Array Biopharma Inc (NASDAQ:ARRY) will be releasing its Q216 earnings data before the market opens on Tuesday, February 2nd. Analysts expect Array Biopharma to post earnings of ($0.06) per share and revenue of $32.70 million for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Array Biopharma (NASDAQ:ARRY) last issued its earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. During the same period in the previous year, the company earned ($0.21) EPS. The company earned $16.20 million during the quarter, compared to analysts’ expectations of $14.02 million. Array Biopharma’s quarterly revenue was up 166.9% on a year-over-year basis. On average, analysts expect Array Biopharma to post $-0.48 EPS for the current fiscal year and $-0.53 EPS for the next fiscal year.

In other news, major shareholder Redmile Group, Llc acquired 75,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 12th. The stock was acquired at an average cost of $3.60 per share, for a total transaction of $270,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently issued reports on the company. Piper Jaffray restated a “buy” rating on shares of Array Biopharma in a report on Wednesday, December 16th. Zacks Investment Research upgraded Array Biopharma from a “hold” rating to a “strong-buy” rating and set a $6.00 target price for the company in a report on Monday, October 5th. Leerink Swann restated an “outperform” rating and issued a $6.00 target price (down previously from $9.00) on shares of Array Biopharma in a report on Thursday, December 17th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $13.00 target price on shares of Array Biopharma in a report on Thursday, December 17th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Array Biopharma presently has an average rating of “Buy” and a consensus price target of $9.69.

Shares of Array Biopharma Inc (NASDAQ:ARRY) opened at 3.02 on Friday. The stock has a 50 day moving average price of $3.80 and a 200 day moving average price of $4.94. Array Biopharma Inc has a 12 month low of $2.97 and a 12 month high of $8.59. The stock has a market cap of $430.71 million and a P/E ratio of 26.73.

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (NASDAQ:ARRY), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

12 Month Chart for NASDAQ:ARRY

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Array Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array Biopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.